Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04210141Phase 2Suspended

Optimal Dose of Antivenom for Daboia Siamensis Envenomings

Role: lead

NCT03217851Completed

Prevalence Survey of Antimalarial Drug Resistance Markers

Role: collaborator

NCT04781426Completed

PrEP Among MSM and TG in Myanmar

Role: lead

NCT03158857Withdrawn

Hepatitis C Treatment Study in Myanmar

Role: lead

NCT01872702Not ApplicableCompleted

Targeted Chemo-elimination (TCE) of Malaria

Role: collaborator

NCT03847870Completed

Rickettsiae in Myanmar

Role: lead

NCT03578133Completed

Causes of Pneumonia in Yangon

Role: lead

NCT03269266Completed

Scrub Typhus RDT Study

Role: lead

All 8 trials loaded